InDex Pharmaceuticals Holding AB (publ) interim report January – June 2020
Focus on phase III preparations“The commercial preparations have confirmed our belief in the potential of cobitolimod, where we estimate that the annual sales at a successful commercialisation can reach more than USD 1 billion,” says Peter Zerhouni, CEO of InDex Pharmaceuticals. Period April – June 2020 · Net sales amounted to SEK 0.0 (0.0) million · Operating loss amounted to SEK –15.6 (–17.7) million · Result after tax amounted to SEK –15.6 (–17.7) million, corresponding to SEK –0.17 per share (–0.26) before and after dilution · Cash flow from operating activities